Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1

Interventions

pembrolizumab 3venetoclax 2selpercatinib 2obinutuzumab 2ibrutinib 2decitabine and cedazuridine drug combination 2cedazuridine 2Rituximab 2Nivolumab 2Midazolam 2Ipilimumab 2Decitabine 2Crizotinib 2zanubrutinib 1trametinib 1toripalimab 1tocilizumab 1tazemetostat 1tagraxofusp 1sotorasib 1sacituzumab govitecan 1romiplostim 1revumenib 1repotrectinib 1prednisolone phosphate 1prednisolone acetate 1pralsetinib 1polatuzumab vedotin 1pirtobrutinib 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × romiplostim × Clear all
NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Amgen

Phase 1/2 Completed
22 enrolled 13 charts 1 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡